Trichomoniasis Market Insights, Epidemiology, and Market Forecast-2030 (US)
発行: DelveInsight Business Research LLP
ページ情報: 英文 66 Pages
DelveInsight's 'Trichomoniasis Market Insights, Epidemiology, and Market Forecast-2030' report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends of Trichomoniasis in the United States.
The Trichomoniasis market report provides analysis regarding current treatment practices, an emerging drug, like Secnidazole (Lupin Research Inc), potential therapies, market share of the individual therapies, historical, current, and forecasted Trichomoniasis market size from 2017 to 2030 for the United States.
The report also covers current Trichomoniasis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the market's underlying potential.
Study Period: 2017-2030
Trichomoniasis (TRIK-uh-muh-NEYE-uh-suhss) or "trich" is a sexually transmitted infection (STI) caused by a parasite; the parasite is spread most often through vaginal, oral, or anal sex. The condition has various public health ramifications and has been associated with vaginitis, cervicitis, urethritis, and pelvic inflammatory disease (PID). Furthermore, it is one of the most common STIs in the United States and affects more women than men. Although it is treated easily with antibiotics, many women do not show any symptoms.
Symptoms can come and go but about 70% of infected people do not have any signs or symptoms. When trichomoniasis does cause symptoms, they can range from mild irritation to severe inflammation. Some people with symptoms get them within 5-28 days after being infected, but others do not develop symptoms until much later. The reason for this is unclear.
This chapter covers the details of conventional and current medical therapies available in the Trichomoniasis market to treat the condition. It also provides the country-wise Trichomoniasis treatment guidelines across the United States.
DelveInsight's Trichomoniasis market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, types, grading, pathophysiology, and diagnosis. It also provides Trichomoniasis treatment algorithms and treatment guidelines in the US.
The Trichomoniasis epidemiology chapters provide insights about historical and current Trichomoniasis patient pool and forecasted trends for the US. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Trichomoniasis epidemiology is segmented by Diagnosed Prevalent Cases of Trichomoniasis, Gender-specific Cases of Trichomoniasis, Cases of Trichomoniasis by Age and Type-specific Cases of Trichomoniasis. The report includes a thorough analysis of all segmentations.
In the US, the cases of Trichomoniasis were 2,570,002 in 2017. Moreover, the Gender-specific cases of Trichomoniasis were highest among females and were reported to be 2,073,893 in the country.
According to DelveInsight's analysis, In the United States, the highest number of Trichomoniasis cases are among 40-49 years of age group followed by 30-39 years.
In the United States, approximately 70% of the Trichomoniasis cases are asymptomatic.
The drug chapter segment of the Trichomoniasis report encloses the detailed analysis of Trichomoniasis pipeline drug. It also helps understand the Trichomoniasis clinical trial details, expressive pharmacological action, the included drug's agreements, and the latest news and press releases.
Treatment is focused entirely on managing symptoms and supporting the health and well-being of the affected child or adult. The management of Trichomoniasis revolves around the appropriate therapies for the physical and neurological problems encountered in the condition and provision for the special educational needs, given the precise cognitive profiles and behavioral features of the condition. There are many upcoming mono and combinational therapies such as Secnidazole (Lupin Research Inc), etc., for the treatment of Trichomoniasis in the pipeline.
The Trichomoniasis market size is expected to increase at a significant CAGR during the study period (2017-2030). The United States accounts for the Trichomoniasis market size, with USD 30.8 million in 2017.
This section focusses on the rate of uptake of the potential drugs in the Trichomoniasis market that are expected to get launched in the market during the study period 2017-2030. The analysis covers Trichomoniasis market uptake by drugs, patient uptake by therapies, and sale of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of Trichomoniasis market is anticipated to experience a positive shift in the coming years owing to the expected launch of emerging therapies.
The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Trichomoniasis key players involved in developing targeted therapeutics.
The report covers the detailed information of Trichomoniasis collaborations, acquisition and merger, licensing, patent details, and other information for Trichomoniasis emerging therapies.
Approaching reimbursement, proactively, can positively impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
To keep up with current market trends, we take KOLs and SME's opinion working in Trichomoniasis domain through primary research to fill the data gaps and validate our secondary research. This will support the clients in potential upcoming novel treatment by identifying the market's overall scenario and the unmet needs.
We perform Competitive and Market Intelligence analysis of the Trichomoniasis Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
DelveInsight estimates an increase in Trichomoniasis Market Size during the study period, 2017-2030.
Increasing Prevalence for Trichomoniasis infection and associated complications and increasing demand for Rapid Test Kits and Point of Care
Resistance against the standard of care, Epidemiological Data for T. vaginalis Infection and Economic Burden of Trichomoniasis.
Currently, there are many key pharma players engaged in developing the drug for Trichomoniasis in monotherapy.
Key Players - Lupin Research Inc.
Prevalent Cases of Trichomoniasis, Trichomoniasis cases by Gender, Trichomoniasis cases by Age and Trichomoniasis cases by types.